3M wins BioWhittaker lawsuit:
This article was originally published in Clinica
3M has won the lawsuit brought by BioWhittaker alleging breach of contract of sale and negligent representations regarding European counterparts of patents (see Clinica No 635, p 17). As a result of the decision, BioWhittaker will take a one-time charge against earnings of approximately $3.4 million reflecting expenses it incurred in connection with the suit.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.